CROSS-TENS: Comparison of Two Modes of Transcutaneous Electrical Nerve Stimulation (TENS) in Chronic Neuropathic Radiculalgia

Sponsor
Lille Catholic University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04169477
Collaborator
(none)
74
4
2
34.8
18.5
0.5

Study Details

Study Description

Brief Summary

This study will compare 2 types of Transcutaneous Electrical Nerve Stimulation (TENS) to treat chronic neuropathic pain. TENS involves the application of electrical stimulation to the skin via surface electrodes to stimulate nerve fibres for pain relief.

Condition or Disease Intervention/Treatment Phase
  • Device: CEFAR Primo Pro (TENS device)
N/A

Detailed Description

TENS is already recommended in clinical practice to treat chronic neuropathic pain. The objective of this study is to compare the efficacy of 2 different modes of TENS: conventional TENS (c-TENS) and mixed-frequency TENS (m-TENS). Randomization will determine the mode that the patient has to test during the first month.

Each patient will test successively each mode during 1 month at home (3 sessions 1 hour/day). Then, the patient will test the other mode during the second month. Up to 6 months, the patient will be free to use the mode of TENS he wants.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
74 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Superiority, Prospective, Multicentric, Randomized, Single-blind, Cross-over Study Comparing 2 Modes of Transcutaneous Electrical Nerve Stimulation (TENS) in Chronic Neuropathic Radiculalgia
Actual Study Start Date :
Oct 8, 2019
Anticipated Primary Completion Date :
May 1, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: cTENS-mTENS

Patients randomized in this arm will test cTENS mode first, the subjects will be crossed over to the mTENS form

Device: CEFAR Primo Pro (TENS device)
During the first month: Patients will have to test 3 sessions of TENS 1 hour/day. Depending on their arm assigned by randomization, patients will begin with c-TENS or m-TENS. [Cross-over] During the second month: Patients will test the other type they do not have used yet according to the following scheme: 3 sessions of 1 hour, each day. In this way, all patients will test successively the 2 different modes. After the end of the second month and up to the end of their participation (6 months after randomization) patients will be free to use the mode of TENS they prefer.

Experimental: mTENS-cTENS

Patients randomized in this arm will test mTENS mode first, the subjects will be cross over to the cTENS mode

Device: CEFAR Primo Pro (TENS device)
During the first month: Patients will have to test 3 sessions of TENS 1 hour/day. Depending on their arm assigned by randomization, patients will begin with c-TENS or m-TENS. [Cross-over] During the second month: Patients will test the other type they do not have used yet according to the following scheme: 3 sessions of 1 hour, each day. In this way, all patients will test successively the 2 different modes. After the end of the second month and up to the end of their participation (6 months after randomization) patients will be free to use the mode of TENS they prefer.

Outcome Measures

Primary Outcome Measures

  1. Change in the visual analog scale for evaluation of radiculalgia (from 0 to 100) [day 30, day 60]

    Visual analogue scales are 10-cm lines anchored at the ends by words that define the bounds of various pain dimensions. The patient is asked to place a vertical mark on the scale to indicate the level of intensity of his or her pain being 0 equivalent to no pain and 100 to the worst possible pain

Secondary Outcome Measures

  1. Patient preference rate [day 60]

    After having tested each mode during one month, the patients will be asked to give their preference (c-TENS or m-TENS)

  2. Patient Global Impression of Change (PGIC) [day 30, day 60]

    Patient Global Impression of Change is a 7-point scale used by the patient to rate the severity of the patient's illness at the time of assessment being 1 equivalent to no change or worsening and 7 to very much improved, making a difference

  3. Rate of patient compliance [day 30, day 60]

    Rate of TENS sessions completed by the patient compared to the number of sessions prescribed for each mode

  4. Rate of patients with adverse events [day 30, day 60, day 180]

    Rate of patients with adverse events definitely or possibly attributable to neurostimulation for each type

  5. Brief pain inventory (impact on daily life) (BPI) [day 30, day 60]

    The BPI allows patients to rate the severity of their pain and the degree to which their pain interferes with common dimensions of feeling and function. There are line drawings of the front and back of a human body on which patients mark the location of their pain. In addition, patients fill out 11 different questions about pain intensity (present as well as least, most, and average for the past 24 hours) and the effect of the pain on their ability to function during various activities of daily living (pain interference items) rated on 0-10 scales being equivalent to no interference and 10 to complete interference.

  6. Mean of post-effect delay [day 60]

    for each mode of TENS, patient estimation between end of a TENS session and return to initial intensity of the pain (calculated from patient journal completed every day during the 2 first months of the study

  7. Visual analog scale for evaluation of radiculalgia one month after [day 30, day 60]

    Visual analogue scales are 10-cm lines anchored at the ends by words that define the bounds of various pain dimensions. The patient is asked to place a vertical mark on the scale to indicate the level of intensity of his or her pain being 0 equivalent to no pain and 100 to the worst possible pain

  8. Visual analog scale for evaluation of radiculalgia six months after [day 180]

    Visual analogue scales are 10-cm lines anchored at the ends by words that define the bounds of various pain dimensions. The patient is asked to place a vertical mark on the scale to indicate the level of intensity of his or her pain being 0 equivalent to no pain and 100 to the worst possible pain

  9. Rate of therapeutic persistence according toTENS mode [day 180]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients aged 18 years old or older

  • Patients with chronic neuropathic radiculalgia from at least 3 months of evolution

  • Radiculalgia VAS > or egal to 40/100

  • Neuropathic pain diagnostic (DN4) score > or egal to 4

  • Patient who has accepted to participate in the study by signing the informed consent form

Exclusion Criteria:
  • Pregnancy

  • Dermatosis in the painful dermatome

  • Venous or arterial thrombosis of the lower limbs

  • Patient with active implantable medical device

  • Severe cognitive disorders

  • Patient under a legal protection regime(guardianship/curatorship/guardianship of justice)

  • Previous use of TENS to treat radiculalgia

Contacts and Locations

Locations

Site City State Country Postal Code
1 CH Béthune Béthune France 62408
2 CHU Lille Lille France 59037
3 GHICL Lomme France 59462
4 CH Roubaix Roubaix France 59100

Sponsors and Collaborators

  • Lille Catholic University

Investigators

  • Principal Investigator: Vincent Ducoulombier, MD, GHICL

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Lille Catholic University
ClinicalTrials.gov Identifier:
NCT04169477
Other Study ID Numbers:
  • RC-P0080
  • 2018-A03074-51 ID RCB
First Posted:
Nov 20, 2019
Last Update Posted:
Apr 5, 2022
Last Verified:
Apr 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Lille Catholic University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 5, 2022